Branched amphiphilic peptides: an alternate non-viral gene delivery system

dc.contributor.authorAvila Flores, Luz Adriana
dc.date.accessioned2014-11-20T19:37:02Z
dc.date.available2014-11-20T19:37:02Z
dc.date.graduationmonthDecemberen_US
dc.date.issued2014-11-20
dc.date.published2014en_US
dc.description.abstractSuccess for gene therapy clinical protocols depends on the design of safe and efficient gene carriers. Nature had already designed efficient DNA or RNA delivery devices, namely virus particles. However, the risk of insertional mutagenesis has limited their clinical use. Alternatively, safer approaches involving non-viral carriers have been and continue to be developed. While they have been reported to be less efficient than viral vectors, adding genome editing elements to pDNA makes the integration of corrective sequence site specific moving non-viral gene delivery systems closer to clinical applications. Over the last decade, peptides have emerged as a new family of potential carriers in gene therapy. Peptides are easy to synthesize, quite stable and expected to produce minimally immunogenic and inflammatory responses. We recently reported on a new class of Branched Amphiphilic Peptides Capsules (BAPCs) that self-assemble into extremely stable nano-spheres. BAPCs display a uniform size of _20 nm if they are incubated at 4_C and they retain their size at elevated temperatures. In the presence of DNA, they can act as cationic nucleation centers around which DNA winds generating peptide-DNA complexes with a size ranging from 50nm to 100nm. However, if BACPs are not incubated at 4_C, the pattern of interaction with DNA differs. Depending of the peptide/DNA ratios, the peptides either coat the plasmid surface forming nano-_bers (0.5-1 _M in length) or condense the plasmid into nano-sized structures (100-400nm). Different gene delivery efficiencies are observed for the three types of assemblies. The structure where the DNA wraps around BAPCs display much higher transfection efficiencies in HeLa cells in comparison to the other two morphologies and the commercial lipid reagent Lipofectinr. As a proof of concept, pDNA was delivered in vivo, as a vaccine DNA encoding E7 oncoprotein of HPV-16. It elicited an immune response activating CD8+ T cells and provided anti-tumor protection in a murine model.en_US
dc.description.advisorJohn M. Tomichen_US
dc.description.degreeDoctor of Philosophyen_US
dc.description.departmentDepartment of Biochemistry and Molecular Biophysicsen_US
dc.description.levelDoctoralen_US
dc.description.sponsorshipTerry Johnson Cancer Center National Institutes of Healthen_US
dc.identifier.urihttp://hdl.handle.net/2097/18701
dc.language.isoenen_US
dc.publisherKansas State Universityen
dc.subjectCelullar biologyen_US
dc.subjectMolecular biologyen_US
dc.subjectBiochemistryen_US
dc.subjectChemistryen_US
dc.subjectBiophysicsen_US
dc.subject.umiBiogeochemistry (0425)en_US
dc.subject.umiBiophysics (0786)en_US
dc.subject.umiCellular Biology (0379)en_US
dc.titleBranched amphiphilic peptides: an alternate non-viral gene delivery systemen_US
dc.typeDissertationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
LuzAdrianaAvilaFlores2014.pdf
Size:
42.26 MB
Format:
Adobe Portable Document Format
Description:
Dissertation
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.62 KB
Format:
Item-specific license agreed upon to submission
Description: